Allcyte

Vienna, Austria Founded: 2017 • Age: 9 yrs Acquired By Exscientia
Developer of drugs for the treatment of cancer patients
Annual revenue - Latest available
Total funding $6.0M 2 rounds
Employees - Tracked headcount
Investors 7 Known backers
Products - Services tracked
Competitors 3 Brand Intelligence

About Allcyte

Allcyte is a company based in Vienna (Austria) founded in 2017 was acquired by Exscientia in June 2021. Allcyte has raised $6 million across 2 funding rounds from investors including Exscientia, EIT Health and 42 Capital. Allcyte operates in a competitive market with competitors including DINmotion and Drug Dosing Predictions, among others.

  • Headquarter Vienna, Austria
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $6 M (USD)

    in 2 rounds

  • Latest Funding Round
    $6 M (USD), Seed

    Mar 25, 2021

  • Investors
    Exscientia

    & 6 more

  • Employee Count
    Not available
  • Acquired by
    Exscientia

    (Jun 15, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Allcyte

Allcyte has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $6 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Allcyte

Allcyte has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Exscientia, EIT Health and 42 Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage technology companies are invested in across Europe.
Locked Locked Locked
Venture capital firm investing in AI & life science sectors
Locked Locked Locked
Amino Collective is engaged in backing innovative startup founders.
Locked Locked Locked
Premium access

Investor details for Allcyte

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Allcyte

Investments
Premium access

Investment portfolio details for Allcyte

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Allcyte

Premium access

Detailed financials for Allcyte

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Allcyte Comparisons

Allcyte Primary company
Description
Developer of drugs for the treatment of cancer patients
Location
Vienna, Austria
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Allcyte

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Allcyte

Allcyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DINmotion and Drug Dosing Predictions, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Offers PBPK models and data solutions for optimizing pharmaceutical drug development processes.
Locked Locked Locked
Offers comprehensive tools for informed drug development and dosing predictions.
Premium access

Detailed competitors of Allcyte

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Allcyte

Premium access

Complete news archive for Allcyte

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Allcyte

Allcyte was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Allcyte is headquartered in Vienna, Austria.

Allcyte is a funded company, having raised a total of $6M across 2 funding rounds to date.

Developer of drugs for the treatment of cancer patients. It offers Pharmacoscopy high-content imaging platform that supports pre-clinical drug development and clinical decision making services. It enables research through the image-based quantification of single-cell phenotypes. It helps pharmaceutical companies to locate the most promising indications for their drug candidates, and doctors use it to find the correct drug for the right patients.

Allcyte's top competitors include DINmotion and Drug Dosing Predictions.

Allcyte has 7 investors. Key investors include Exscientia, EIT Health, 42 Capital, Air Street Capital, and PUSH VC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available